Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Poxel    POXEL   FR0012432516

POXEL

(POXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Poxel : Corporate Presentation - English

10/11/2020 | 08:25pm EST

Corporate Presentation

October 2020

1

Disclaimer

Some of the statements contained in this presentation constitute forward-looking statements. Statements that are not historical facts are forward-looking statements. Forward-looking statements generally can be identified by the use of forward- looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue" or similar terminology. These statements are based on the Company's current strategy, plans, objectives, assumptions, estimates and projections. Investors should therefore not place undue reliance on those statements. The Company makes no representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Forward-looking statements speak only as of the date that they are made and the Company does not undertake to update any forward-looking statements in light of new information or future events. Forward- looking statements involve inherent risks and uncertainties. The Company cautions that a number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company is regularly reviewing the impact of the outbreak on its business. As of the date of this presentation, and based on publicly available information, the Company has not identified the occurrence of any material negative effect on its business due to the COVID-19 pandemic that remains unresolved. However, the Company anticipates that the COVID-19 pandemic could have further material negative impact on its business operations. The worldwide impact of COVID-19 may notably affect the Company's internal organization and efficiency, particularly in countries where it operates and where confinement measures are implemented by the authorities. In addition, COVID-19 may impact market conditions and the Company's ability to seek additional funding or enter into partnerships. Particularly, delays in the supply of drug substance or drug products, in the initiation or the timing of results of preclinical and/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could potentially have an impact on the Company's development programs and partnered programs. The Company will continue to actively monitor the situation.

2

Mission and Vision

To discover, develop and commercialize innovative therapies for patients suffering from serious chronic diseases with underlying metabolic pathophysiology

  • Mid-to-latestage first-in-class pipeline: Type 2 diabetes (globally partnered) and NASH
  • Pipeline expansion in chronic and rare metabolic indications
  1. Internal AMPK* and D-TZD# Platforms o External Opportunities

Targeting Defects in Cellular Metabolism

acetyl CoA

METABOLICINFLAMMATION DISORDERS

(cellular energy

homeostasisTISSUE

imbalances) DEGENERATION & CELL DEATH

apoptosis,

necrosis

Leveraging AMPK & D -TZD Platforms

Metabolic Component + Unmet Medical Need

  • Hereditary Metabolic Disorders: e.g. adrenoleukodystrophy
  • Endocrinopathies
  • Renal Diseases:
    e.g. diabetic nephropathy, polycystic kidney disease, others
  • Other: rare, orphan indications

*AMP activated protein kinase; # Deuterium-stabilized thiazolidinediones

3

Three Mid-to-Late Stage First-in-Class Drug Candidates with Novel Mechanisms and Differentiated Strategies

Global

Partnerships

Novel Mechanisms with Platform Expansion

Proprietary Programs

Cash &

Equiv. EUR 46M (USD 51.5M) as of 6/30/20

Imeglimin

(T2D)

AMPK

PXL770*Platform

PXL065** D-TZD

Platform

Other

Chronic and

Leveraging

Rare

Metabolic

Platforms &

Indications

External

Opportunities

Anticipated first product launch in Japan in 2021 through Imeglimin partnership with Sumitomo Dainippon Pharma

Several significant milestones in 2020 including results in NASH & other metabolic indications

Highly experienced management team; extensive metabolic R&D expertise & track record in US, EU and Japan

Global company with presence in 3 countries (France, US and Japan); listed on Euronext Paris

  • *PLX770 direct AMP-kinase activator (AMPK) from platform **PXL065 deuterium-stabilizedR-pioglitazone (mitochondrial pyruvate inhibitor) from D-TZD (deuterated thiazolidinediones) platform

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Poxel SA published this content on 11 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 October 2020 00:24:02 UTC


© Publicnow 2020
All news about POXEL
11/30POXEL : to Host Virtual NASH Investor Event with Leading Experts on December 14,..
BU
11/23Poxel Provides Update on Metavant Partnership with Imeglimin
AQ
11/23POXEL : Corporate Presentation - English
PU
11/20POXEL : Provides Update on Metavant Partnership with Imeglimin
BU
11/17POXEL : Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data f..
AQ
11/16POXEL : Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data f..
BU
11/10POXEL : Corporate Presentation - English
PU
11/09POXEL : Announces Upcoming Poster Presentations at AASLD The Liver Meeting® 2020
BU
10/28Poxel Announces Participation at Several Upcoming Scientific and Investor Con..
AQ
10/27POXEL : Announces Participation at Several Upcoming Scientific and Investor Conf..
BU
More news
Financials
Sales 2020 7,93 M 9,63 M 9,63 M
Net income 2020 -30,7 M -37,3 M -37,3 M
Net cash 2020 11,0 M 13,4 M 13,4 M
P/E ratio 2020 -5,58x
Yield 2020 -
Capitalization 188 M 227 M 228 M
EV / Sales 2020 22,3x
EV / Sales 2021 4,38x
Nbr of Employees 51
Free-Float 75,3%
Chart POXEL
Duration : Period :
Poxel Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends POXEL
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 18,17 €
Last Close Price 6,60 €
Spread / Highest target 218%
Spread / Average Target 175%
Spread / Lowest Target 150%
EPS Revisions
Managers
NameTitle
Thomas Kuhn Chief Executive Officer & Director
Pierre Legault Chairman
Sebastien Bolze Chief Operating Officer & Executive Vice President
Anne Renevot Chief Financial Officer & Executive Vice President
Sophie Hallakou-Bozec Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
POXEL-45.90%227
GILEAD SCIENCES, INC.-5.92%76 628
VERTEX PHARMACEUTICALS3.54%58 951
REGENERON PHARMACEUTICALS34.64%53 359
WUXI APPTEC CO., LTD.64.21%39 880
BIONTECH SE257.41%29 157